Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bladder disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    473 result(s) found for: Bladder disease. Displaying page 2 of 24.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-003048-52 Sponsor Protocol Number: 527.51 Start Date*: 2007-10-29
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A Phase IIb/III, multi-centre, double-blind, randomised, placebo-controlled, dose ranging study of tamsulosin hydrochloride (low, medium and high dose) as treatment in children with neuropathic bla...
    Medical condition: Neurogenic Bladder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029279 Neurogenic bladder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004311-12 Sponsor Protocol Number: RUTIVAC-1 Start Date*: 2017-02-14
    Sponsor Name:ARCHIVEL FARMA, S.L.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II TRIAL TO EVALUATE THE IMMUNOMODULATORY EFFECT OF RUTI® IN INDIVIDUALS WITH HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC) TREATED WITH ...
    Medical condition: High-Risk Non-Muscle-Invasive Bladder Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-006433-13 Sponsor Protocol Number: TNG-CL008 Start Date*: 2008-06-11
    Sponsor Name:Tengion Inc.
    Full Title: An open-label, multicentre study of augmentation cystoplasty using an autologous Neo-Bladder construct in subjects with spina bifida.
    Medical condition: Neurogenic bladder secondary to spina bifida
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029279 Neurogenic bladder LLT
    9.1 10041524 Spina bifida LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-001943-23 Sponsor Protocol Number: EFC6668 Start Date*: 2007-12-17
    Sponsor Name:Sanofi-Aventis Recherche et Développement
    Full Title: Randomized Study of LAROTAXEL + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer
    Medical condition: Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005003 Bladder cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Prematurely Ended) ES (Completed) SE (Prematurely Ended) FR (Completed) BE (Completed) IT (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003112-27 Sponsor Protocol Number: NORTH-REG-3 Start Date*: 2020-09-14
    Sponsor Name:Aarhus University [...]
    1. Aarhus University
    2.
    Full Title: Nordic Urothelial Cancer Research Group Study on Reduced BCG Dwell-Time in High Risk NMIBC Short title: NORTH-REG Dwell-Time Study
    Medical condition: Reduced BCG dwell time in patients who are diagnosed with high risk non-muscle-invasive- bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10005004 Bladder cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000557-36 Sponsor Protocol Number: UC-Aurora_INT01 Start Date*: 2014-08-21
    Sponsor Name:Fondazione IRCCS Istituto Nazionale dei tumori
    Full Title: A Phase 2 study of the Aurora kinase A inhibitor Alisertib (MLN8237) in patients with relapsed or refractory transitional-cell carcinoma of the bladder and urothelial tract
    Medical condition: Advanced urotelial cancer of the bladder, urethra, or the upper urinary tract who are resistant to platinum based therapy
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005427-10 Sponsor Protocol Number: 1200.261 Start Date*: 2016-04-29
    Sponsor Name:Boehringer Ingelheim España, S.A.
    Full Title: Phase II open label single arm exploratory trial of oral afatinib monotherapy following platinum failure for patients with advanced/metastatic urothelial tract carcinoma with ERBB receptor deregula...
    Medical condition: patients with advanced/metastatic urothelial tract carcinoma with ERBB receptor deregulation
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-005948-29 Sponsor Protocol Number: BL011 Start Date*: 2022-03-09
    Sponsor Name:UroGen Pharma Ltd.
    Full Title: A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients with Low Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) a...
    Medical condition: Non-Muscle Invasive Bladder Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Trial now transitioned) LV (Trial now transitioned) AT (Trial now transitioned) LT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001883-48 Sponsor Protocol Number: D933SC00001 Start Date*: 2018-11-28
    Sponsor Name:Astrazeneca AB
    Full Title: Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab ...
    Medical condition: Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-002143-83 Sponsor Protocol Number: 191622-515 Start Date*: 2006-07-25
    Sponsor Name:Allergan Ltd
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of a Single Treatment with Two Dose Levels of BOTOX® (Botulinum Toxin Type A) Purified N...
    Medical condition: Urinary Incontinence Due to Neurogenic Detrusor Overactivity
    Disease: Version SOC Term Classification Code Term Level
    9.0 10029279 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) AT (Completed) CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2014-003625-17 Sponsor Protocol Number: CA209-275 Start Date*: 2015-01-27
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A phase II single arm clinical trial of nivolumab (BMS-936558) in subjects with metastatic or unresectable urothelial cancer who have progressed or recurred following treatment with a platinum agen...
    Medical condition: metastatic or unresectable urothelial cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046723 Urothelial carcinoma ureter LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046714 Urothelial carcinoma bladder LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064467 Urothelial carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046728 Urothelial carcinoma urethra LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) BE (Completed) SE (Completed) CZ (Completed) FI (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-005452-38 Sponsor Protocol Number: D910PC00001 Start Date*: 2021-11-18
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With En...
    Medical condition: Cisplatin ineligible patients with histologically or cytologically documented muscle-invasive transitional cell carcinoma (TCC) of the bladder.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10005004 Bladder cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) AT (Trial now transitioned) PL (Trial now transitioned) NL (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-005330-58 Sponsor Protocol Number: SAKK06/14 Start Date*: 2016-08-22
    Sponsor Name:SAKK (Schweizerische Arbeitsgemeinschaft für klinische Krebsforschung)
    Full Title: A phase I/II open label clinical trial assessing safety and efficacy of intravesical instillation of VPM1002BC in patients with recurrent non-muscle invasive bladder cancer after standard BCG therapy
    Medical condition: Treatment of patients with recurrent non-muscle invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005005 Bladder cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-011049-15 Sponsor Protocol Number: IB 2009–08 Start Date*: 2009-06-29
    Sponsor Name:Institut Bergonié - Département d’Oncologie Médicale
    Full Title: Evaluation de l’efficacité du temsirolimus chez des patients récidivant d’un cancer de la vessie après une première ligne de chimiothérapie. Essai clinique de phase II multicentrique.
    Medical condition: Cancer de la vessie récidivant
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028983 Neoplasm bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-002408-26 Sponsor Protocol Number: 42756493BLC2001 Start Date*: 2015-04-16
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects with Metast...
    Medical condition: Urothelial cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Completed) IT (Completed) DE (Completed) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) RO (Ongoing) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003407-12 Sponsor Protocol Number: 191622-518 Start Date*: 2008-02-19
    Sponsor Name:Allergan Limited
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Explore the Dose Dependent Response to Three Dose Levels of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin ...
    Medical condition: Neurogenic detrusor overactivity as a result of spinal cord injury, in patients with urinary incontinence, who have not been adequately managed with anticholinergic therapy.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029279 Neurogenic bladder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) GR (Completed)
    Trial results: View results
    EudraCT Number: 2010-022653-41 Sponsor Protocol Number: INT52/10 Start Date*: 2010-11-25
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Phase II study of neoadjuvant cisplatin and gemcitabine plus sorafenib for patients with transitional cell carcinoma of the bladder.
    Medical condition: Muscle-invasive transitional cell carcinoma of the bladder at clinical stage T>/=2N0.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005084 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005455-37 Sponsor Protocol Number: 178-CL-207 Start Date*: 2022-11-14
    Sponsor Name:Astellas Pharma Global Development Inc.
    Full Title: A Phase 3, Open Label, Multicenter, Baseline-Controlled Sequential Dose Titration Study Followed by a Fixed Dose Observation Period to Evaluate Pharmacokinetics, Efficacy and Safety of Mirabegron P...
    Medical condition: Neurogenic detrusor overactivity (NDO)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10012547 Detrusor hyperreflexia LLT
    23.1 100000004857 10059617 Overactive bladder LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-019181-91 Sponsor Protocol Number: EAURF2008-01 Start Date*: 2013-05-24
    Sponsor Name:EAU Foundation for Urological Research
    Full Title: Treatment of High Grade Non-Muscle Invasive Urothelial Carcinoma of the Bladder by Standard Number and Dose of Intravesical BCG Instillations Versus Reduced Number of Intravesical Instillations wi...
    Medical condition: Non muscle invasive bladder cancer after transurethral resection of the Bladder Tumor (TURT).
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Prematurely Ended) BE (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004671-19 Sponsor Protocol Number: PDX 011 Start Date*: 2008-06-06
    Sponsor Name:Allos Therapeutics, Inc.
    Full Title: A Phase 2, Single-Arm Study of Pralatrexate in Patients with Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder
    Medical condition: Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007294 Carcinoma bladder recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) ES (Ongoing) BE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 07:49:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA